Ovarian cancer: State of the art and future directions

The median survival of patients with ovarian cancer has increased steadily, mainly due to a multidisciplinary approach including surgery and chemotherapy. This editorial article summarizes the important messages taken from clinical research performed in this field over the last 15 years. It deals with the following issues: screening, prevention, management of early and advanced disease, maintenance/consolidation therapies and the treatment of relapsing patients. It also gives some future directions with the hope to improve the management and the outcome of this highly lethal disease.

Ovarian cancer; Disease management; Chemotherapy

[1] Petricoin E.F., Ardekani A.M., Hitt B.A. et al.: "Use of proteomic patterns in serum to identify ovarian cancer". Lancet, 2002, 359, 572.

[2] Kauff N.D., Satagopan J.M., Robson M.E. et al.: "Risk-reducing salpingo-oophorectomy in women with a BRCA 1 or BRCA2 mutation". N. Engl. J. Med., 2002, 346, 1609.

[3] Ozols F.: "Controversies in ovarian cancer". Proceedings of the I 5,h International Congress on Anti-Cancer Treatment, Paris, France, 09-12/02/2004 (educational lecture, 83).

[4] Trimbos J.B., Parmar M., Vergote I. et al.: "International collaborative ovarian neoplasm trial I and adjuvant chemotherapy in ovanan neoplasm trial: t wo parallel randomized pha、e III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma" J. Natl. Cancer Inst., 2003, 95, 105.

[5] Mano M., Awada A., Minisini A. et al.: "Remaining controversies in the upfront management of advanced ovarian cancer". Inter. J. Gynaecol. Cancer, 2004 (still in press)

[6] "Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicm, and cisplatin in women with ovarian cancer: the ICON3 randomized trial". Lancet, 2002, 360, 505.

[7] Gordon A.N. et al.: "Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan". J. Clin. Oneal., 2001, 19, 3312.

[8] Ferrero J.M. et al.: "Caelyx and paraplatine in patients with advanced ovarian cancer in late relapse: a gineco phase II trial". Abstract, 828, ASCO, 2002.

[9] Parmar M.K., Ledermann J.A., Colombo N. et al.: "Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial". Lancet, 2003, 361, 2099.